Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 9/20 | 0.56 |
| ▸ | CACNB1 | Q02641 | 9/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 7/20 | 0.56 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14606169 | 0.84 | CACNA2D1 (0.61) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL2292927 | 0.84 | ADRB1 (0.51) | TSHRALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3860597 | 0.81 | CACNA2D1 (0.61) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL5024628 | 0.80 | CACNA2D1 (0.70) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL26330969 | 0.80 | CACNA2D1 (0.81) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL3794409 | 0.80 | ME2 (0.68) | TSHRALDH1A1MAPTMEN1CYP2C19 | |
| SCHEMBL5026259 | 0.80 | CACNA2D1 (0.56) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL3794406 | 0.79 | CNR1 (0.52) | GAATSHRALDH1A1MAPTMEN1 | |
| SCHEMBL4456969 | 0.78 | TSHR (0.51) | GAATSHRALDH1A1MAPTLMNA | |
| SCHEMBL2021224 | 0.77 | MAPT (0.66) | GAATSHRALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | claimed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1871372-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | disclosed |
| WO-2006105670-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | CACNA2D1 36/4885CACNA1B 1/4885CACNB1 13/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | CACNA2D1 90/4885CACNA1B 1/4885CACNB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.